Plexision, a US-based biotechnology company, has initiated overseas operations with the establishment of a reference laboratory in Hyderabad, India. This laboratory will offer a comprehensive range of tests for transplant patients.

These tests include the company’s exclusive personalised transplant diagnostic tests to predict rejection and viral infections, as well as drug level monitoring, pharmacogenomics, and genetic testing. The company’s products were showcased at the Annual meeting of the Indian Society for Organ Transplantation in Nagpur, India, this week, and will become available later this year.

“The success of anti-rejection medications depends on the unique metabolic, immunological and genetic makeup of each individual”, said Ravi Mohanka, MD, President of the Indian Society of Transplantation, and Director of Liver Transplantation at the Sir H.N Reliance Foundation Hospital and Research Center in Mumbai, India.

“Plexision’s test systems can define this complex makeup to personalise care and improve outcomes in the rapidly growing transplant recipient population in India” said Rajeev Sindhi, CEO of Plexision.